Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of lunresertib alone and in combination with RP-3500 or Debio 0123 in molecularly selected advanced solid tumors
NL-OMON60930Phase 1Completed
- Sponsor
- Debiopharm
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lunresertib in Nonhematologic neoplasms, ovarian cancer, fallopian tube cancer (PFTC) and 1 more (6 arms), sponsored by Debiopharm. Primary endpoints: Safety and tolerability, Dose-limiting toxicities and 4 more. Started Jun 2021; status: completed.
02
Drugs
lunresertib
03
Conditions
Nonhematologic neoplasmsovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON60930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60930.